Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

More News! 31 Jan 2019

Watch Strap Made of Recombinant Spider Silk Launches in Europe

Sold by the luxury brand Omega, the watch strap is made with spider silk proteins that are brewed by genetically engineered bacteria. Spider silk is known in the textile industry for its strength, resilience, flexibility and light weight. However, it is not possible to ‘farm’ spiders to produce their silk at an industrial scale. The […]

January 31, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

UK Policy Antimicrobial Resistance Biotech

News and Trends 28 Jan 2019

New UK Policy Benefits Biotechs Waging War on Superbugs

Among other measures, the new policy changes the way companies are reimbursed for antimicrobial drugs, which is expected to increase investment in biotech and the interest of big pharma in tackling antimicrobial resistance. Antimicrobial resistance is a huge problem. More and more pathogens are becoming resistant to antibiotics, as seen in the rising number of […]

January 28, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 28 Jan 2019

5 Real-Life Technologies Where Biotech Meets Science Fiction

From genetic engineering to synthetic food and immortality, biotech is getting surprisingly close to recreating science fiction in real life. Science fiction is always a step ahead of real-life science. The genre imagined space travel, wireless communication and virtual reality years before they became a reality. In fact, sci-fi has coined some scientific terms […]

January 28, 2019 - 6 minutesmins - By Clara Rodríguez Fernández

In Depth 22 Jan 2019

No Guts, No Glory: How Microbiome Research is Changing Medicine

Scientists are uncovering many ways that the microorganisms that share our body can influence our health. It appears as though the human microbiome could be the key to treating all sorts of diseases, but how can we make these tiny creatures collaborate with us? Let’s do a gut check. We’ve all been told that our […]

January 22, 2019 - 10 minutesmins - By Clara Rodríguez Fernández

Interview 16 Jan 2019

The Coming of Age of Biotechnology

Since its beginnings in the 1970s, the biotech industry has grown massively and made huge advances. At our recent Labiotech Refresh in London, Tim Haines, Managing Partner at the life science VC Abingworth, shared his views on how biotechnology has finally come of age. Haines knows the biotech industry well. After leading and helping sell […]

January 16, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Jan 2019

AI Drug Discovery Company Raises €23M and Signs with Roche

Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with Roche worth up to €60M. Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech. “We can reduce at least 4- to 5-fold the time and cost of drug discovery as compared to the industry […]

January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Jan 2019

Swiss Firm Raises €67M to Take Genomics AI to Hospitals

SOPHiA GENETICS has completed a $77M (€67M) funding round that will expand the use of its artificial intelligence technology for genomics into hospitals across the world. The funding will mainly go towards the recruitment of new employees. The goal is to increase the number of hospitals using SOPHiA’s AI technology, particularly in the US, where […]

January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 7 Jan 2019

15 European Biotech Companies to Watch in 2019

As 2018 drew to a close, we had a look at how many companies had been doing and what their prospects were for the new year. It’s hard to narrow it down, but we think these European biotechs are going to make headlines this year. Last year was a great year for biotech in Europe. […]

January 7, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Dec 2018

French Scientists Find a Weak Spot in HIV-Infected Cells

Researchers at the Institut Pasteur were able to selectively kill the cells where HIV hides from antiretroviral drugs, opening the way for a new form of HIV treatments. The reason why HIV comes back when a person stops taking antiretroviral therapy is that it remains hidden and undetected within immune T cells. In a study […]

December 21, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2018

Personalized Immunotherapy for Brain Cancer Succeeds in Clinical Trials

A European trial has proved the feasibility and efficacy of treating cancer with a personalized immunotherapy tailored to each patient. The phase I/II trial, run across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma, an aggressive form of brain cancer. The first vaccine was designed to immunize the patients […]

December 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Morphogen IX pulmonary arterial hypertension

More News! 20 Dec 2018

Cambridge Company Raises €20M for Potential First in Lung Disease

Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become the first to treat the condition rather than just addressing the symptoms. People with pulmonary […]

December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández

Altheia Science gene therapy autoimmune disease

News and Trends 19 Dec 2018

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

Altheia Science, based in Milan, has raised €17M to fund the development of gene therapies for autoimmune diseases with the remarkable potential to be curative. “The success of our fundraising campaign is unprecedented over a Series A in Italy,” said Paolo Rizzardi, co-founder and CEO of Altheia. The funds will go towards taking the company’s […]

December 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us